



Index

Note: page numbers in *italics* refer to figures, those in **bold** refer to tables. Illustrations in the Plate Section are indicated by Plate number.

- acetylcholine receptors 61
acid blob activator 321
acquired immune deficiency syndrome *see* AIDS
actin fibers, HSV-induced changes 134, 135
acycloguanosine (acG) 107, 108
acyclovir 107, 108
adeno-associated virus (AAV) 305–6
 gene delivery 388
 latent infection 306, 389
cyclic adenosine monophosphate (cAMP) 199
adenovirus **23**, 38
 capsid
 proteins 149, 150, 151
 structure 301
 DNA 287
 replication 301–3
 E1A gene 301, 302
 E1B protein 301, 302
 E2 region 301, 302
 gene delivery 388
 genome 301, 302
 host interactions 303
 polyadenylation site use changes 303
 replication 135, 299, 301–3, 304
 serotypes 88
 transformation of nonpermissive cells 303
 tumor suppressor gene function blocking 371
 VARNA 301, 303
adjuvants 101
aerosol, viral 19, 21, 24
agnoproteins 294, 295
AIDS 5, 40, 89
 development 332
 enabling factors for disease 386
 immune dysfunction 86–7
 impact 383, 384–5
 Kaposi's sarcoma 332
 protease inhibitors 235
 T cell destruction 372
 see also HIV
alfalfa looper virus (AcNPV) 333, 334
algal viruses 351–2
Alzheimer's disease, gene therapy 389
amantadine 108–9
amino acid epitopes 78, 79, 81
aminopterin 170
cAMP receptor protein (CRP) 199
amplification, viral 24
aneuploidy 129
animal cells 11, 12
 culture 128–31
 surface 62
 transformation 11, 13
animal models
 herpes simplex virus 33–4
 parameters 27
 pathogenesis 25–34
 poxvirus 27–8
 rabies 30–1, 31–2
 reovirus 28–30
animal pathogens 7
animal viruses, entry into cells 61, 62, 63–4
antibiotic resistance 90
antibodies 77
 antigen-bound 172–3
 Fab region 167
 Fc region 168, 172, 173, 174, 175–6
 measurement of antiviral 91–5
 structure 167–8
antibody–antigen complexes 93–4
 bacterial proteins for detection/isolation 173–4, 174–5
antigen(s), viral 18, 39, 77
antibodies bound to 172–3
internalization 85
processing 82–3, 83–4
vaccine production 101
antigen presentation
 to immune reactive cells 80–6
 local immunity 82
antigen presenting cells (APCs) 77, 78
 immune response initiation 82–5
 professional 83
antigenic determinants 78, 81
antigenic drift 88
 influenza A 270
antigenic shift, influenza A 271
antisense oligonucleotides 110
antiserum 167
antiviral antibody measurement 91–5
antiviral drugs 106–10
 antisense 110
 HIV protease targeting 73
 precise targeting 110
 resistance reduction/elimination 109–10
 targeting to virus replication cycle 106–10
 therapeutic index 106
 toxicity 106

- antiviral effector molecules (AVEMs) 104, 105
- apathogenic strains 4
- apoptosis 38, 104, 370
- adenovirus 303
- arboviruses 42–3, 57
- see also* arthropod vectors;
- bunyaviruses; togaviruses
- arenaviruses 275–6
- arthropod vectors 22, 24, 57
- bunyaviruses 272, 275
- spread 386
- togaviruses 247
- arthropods, viral infections 333
- atomic force microscopy 123–4
- attachment, viral 60
- attenuation 98, 100
- viral genome 219
- autoimmune disease 87–8
- persistent infections 39
- avian influenza
- in chickens 7
- transmission to humans 272, 384
- avian leukosis virus 361
- avirulent strains 4
- azidothymidine (AZT) 108, 109
- B-cell immunity *see* humoral immunity
- B cells 17, 83
- antibody production 77
- clonal selection 85, 86
- effector 19
- Epstein–Barr virus 18, 331
- immune response 80
- internalizing 85
- maturation 80
- monoclonal antibodies 168, 169, 170
- bacterial antiviral systems 110–11
- bacterial cells 11, 12
- cultures 127–8
- viral infections 14
- bacterial restriction 14, 110–11
- bacterial transposons 373
- bacterial viruses 276
- bacteriophage 6
- DNA injection into *E. coli* 67, 68, 69
- large DNA-containing 342–6, 347, 348–51
- mRNA regulated translation 253–5
- RNA genome replication 253–5
- bacteriophage Φ X174 307–9
- bacteriophage λ
- cro protein 349, 350
- DNA integration 350
- gene expression 348–50
- genome 348
- size 157, 158
- host cell lysis/lysogeny 346, 348, 349, 350
- decision in *E. coli* 350–1
- latency 346, 348–50
- promoters 348–9, 350–1
- prophage generation 350
- reactivation 346, 348–50
- replication 346, 348–50
- termination signals 349
- bacteriophage P22 72–3
- bacteriophage Q β 253–5
- bacteriophage T4 343–6, 347
- assembly 347
- capsid maturation/release 346, 347
- DNA genome 151, 152, 343–4, 345
- genome 343–5
- replication 345–6, 347
- structure 344
- bacteriophage T7 342–3
- baculovirus 333–4
- RNA polymerase encoding 200
- Baltimore classification 57, 58, 232
- biochemical processes 9
- biological activity, viral,
- measurement 136–42
- biological control, baculovirus 334
- biological weapons testing by US 387
- biotechnology, baculovirus 334
- bioterrorism 7, 386–7
- smallpox research 98
- threats 98, 341
- BK virus 38, 288–9, 291
- blood
- hepatitis C virus transmission 43
- pooled fractions 5
- titers of virus 19
- blood products 5, 6
- hepatitis C virus transmission 43
- blood transfusions 5, 6
- blood–brain barrier 41
- bluetongue virus 279
- bornaviruses 258, 259, 266–7
- bovine spongiform encephalopathy (BSE) 10, 282, 283
- brome mosaic virus 66
- replication 252–3
- Bst*EII restriction endonuclease 157, 158
- bunyaviruses 23
- ambisense genomes 274
- encephalitis 275
- gene products 273, 274
- hemorrhagic fever 275
- pathogenesis 275
- replication 272, 273, 274–5
- ribonucleoproteins 273, 274
- structure 272, 273
- vectors 272
- buoyant density differences 145–6
- buried determinants 79
- Burkitt's lymphoma 332, 371
- burst size 11
- C-proteases 235
- Cadang-Cadang viroid 7, 23, 281
- cAMP receptor protein (CRP) 199
- cancer 19, 370–1
- cervical carcinoma 370
- hepatocellular carcinoma 19, 371, 380
- human gamma herpesviruses 312
- oncornavirus transformation 370
- persistent infections 39
- retrovirus-induced 371
- see also* carcinogenesis; oncogenes; oncogenesis
- cancer cells 11, 13
- primary cell transformation 131
- canine distemper 264
- cap-binding protein (CBP1) 202
- cap site 188, 190, 191, 192
- cap snatching/stealing 268, 269
- capillary electrophoresis 152
- capsid proteins
- differing molar amounts 149, 150, 151
- poliovirus 148–9, 150
- stoichiometry 147–8
- capsids 51, 52, 53, 55
- assembly 69, 71–3, 74, 75
- budding 75
- empty 72, 132, 239, 240
- formation 60
- helical 69, 71
- icosahedral 71–3
- symmetry 52, 55
- capsomer 52
- self-assembly 71
- carcinogenesis 370–1
- catabolite repression 199
- cattle prion disease *see* bovine spongiform encephalopathy (BSE)
- cauliflower mosaic virus 380–1
- CCR5 63, 372
- CD4⁺ 18
- CD4 receptor 390
- CD4⁺T cells 61, 63, 83, 372
- CD8⁺T cells 82
- cell(s)
- antigenicity change 134
- biochemical property changes 135–6

- cell(s) (*cont'd*)
- contact inhibition of growth 130
 - fusion 134
 - immortal 170
 - infection outcome 131–6
 - lysis 61
 - complement-mediated 85–6, 87
 - morphology change 134, 135
 - nonpermissive 131–2
 - physical appearance change 133–4, 135
 - transformed foci generation 137, 138
 - tropism 40
 - viral entry 60
 - animal viruses 61, 62, 63–4
 - enveloped 64–5
 - nonenveloped 64
 - plant viruses 65–7
 - viral genome introduction 69, 70
- cell culture techniques 127–31
- cell lines
- continuous 128–9, 130, 131
 - primary 129–30, 131
 - transformed 130, 131
- cell-mediated immunity 77
- measurement 90–1
- central nervous system (CNS) 177, 178
- herpes simplex virus 30
 - infection target 40, 41
 - microglial cells 18
 - polyomavirus 291
 - rabies virus 30–1, 31–2
 - viral spread 17
- centrifugation, rate zonal 146, 156–7
- cervical carcinoma 370
- chemokines 18, 63
- receptors 372
- chicken pox 19, 23, 24, 312
- see also* varicella zoster virus
- Chlorella* viruses 8, 351–2
- chloroplast 8
- chorioallantoic membrane, plaque formation 136
- chromosomal translocation, virus-induced 371
- cI protein 351
- circulatory system, viral spread 17
- cirrhosis 44, 385
- classification schemes 55–7, 58, 59, 232
- disease-based 57, 59
- clearance, viral 19
- clonal selection 85, 86
- co-carcinogens 39, 332–3
- co-receptors 63
- coconut palm loss 7
- cold virus 19, 21, 37, 241
- isolated communities 24–5
- Colorado tick fever virus 279
- Coltivirus* 279
- communications, disease spread 386
- complement cascade 85–6, 87
- complement fixation 93–5
- complementary DNA (cDNA) 136, 159–60
- fluorescent-tagged molecules 183
 - sequence analysis 195–6
- complementation, mutations 216, 217
- confocal microscopy 170–1, 172, Plates 7 and 8
- contact inhibition of growth 130
- coronavirus 23, 37
- cytopathology 251
 - replication/transcription 248–50
- cowpea mosaic virus replication 252
- cowpox 97–8, 338, 341
- coxsackievirus 241
- Creutzfeldt–Jakob disease 10, 282
- variant 10, 283
- cro protein 349, 350
- cryo-electron microscopy 121, 122
- CXCR4 63, 372, 390
- cytochalasin B 234
- cytokines 103, 370
- see also* interferon (IFN)
- cytolysis 61
- cytomegalovirus (CMV) *see* human cytomegalovirus (HCMV)
- cytopathic effect (CPE) 141
- cytopathology 61
- biochemical properties of cells 135–6
 - coronavirus 251
 - picornavirus 239–41
 - plaque formation 136, 137
 - poliovirus 239–41
 - rhabdoviruses 264
 - togavirus 246–8
 - virus-mediated 133–4, 135
- cytotoxic T cells 370
- Dane particles 377
- defective interfering (DI) particles 223
- see also* virus particles, defective
- denaturation temperature 158
- dendritic cells 83
- dengue fever 7, 22, 241, 333
- virus replication 24
- dense bodies 74, 75
- dependovirus 305–6
- Desmodium* yellow mottle virus 55, Plate 2
- developing world
- AIDS spread 5
 - vaccines 100, 102
- diabetes mellitus 19
- dideoxycytidine (ddC) 109
- dideoxyinosine (ddI) 109
- differential display analysis 136
- dilution endpoint methods 140, 141–2
- disease 14
- acute infections 36–7
 - animal models 26–7
 - bunyavirus 275
 - causes 385–6
 - coronavirus 251
 - elimination 387
 - emerging 383–7
 - enabling factors 385–6
 - etiology 59
 - human history impact 6–7
 - long incubation periods 39–40
 - modes of spread of human viruses 21, 22
 - novel virus strain evolution 385
 - picornavirus 239–41
 - poliovirus 239–41
 - rhabdoviruses 264
 - sources 385–6
 - subviral 39–40
 - symptoms 17–18, 19
 - togavirus 246–8
 - viral destruction of other viruses 390
- distemper 264, 265
- DNA 51
- amplification with PCR 160–3
 - automated sequencing 153–4, 155, Plate 5
 - bacterial chromosome 186
 - base polarity 186
 - chemical sequencing 152–3
 - cleavage with restriction endonuclease 208–10
 - complexity measurement 158–60
 - denatured bubble 186–7
 - duplex 186
 - enzymatic sequencing 153, 154–5
 - eukaryotic 186
 - fragment cloning 212–13, 214–15
 - genome length measurement 156
 - hybridization to RNA 179–81
 - lagging strand synthesis 187–8
 - microchips 182, 183
 - origin of replication (ori) site 186, 189
 - prokaryotic 186
 - renaturation rates 158–60

- replication
 - of cellular 186–8, 189
 - vegetative 323
- RNA virus replication 232
- sequence analysis 151–4, 155
- size measurement 158–60
- synthesis detection 177, 178
- transfection 220, 221–2
- vaccines 101
- Watson–Crick base-pairing rules 158, 186, 232
- see also* double-stranded DNA (dsDNA); single-stranded DNA (ssDNA)
- DNA-binding proteins 196
- DNA-containing viruses 8
- DNA ligase 188
- DNA methylases 110
- DNA polymerase 8, 187, 189
- DNA tumor viruses 135
- DNA viruses 51, 53, 56, 286–8
 - concatamers 287
 - cytoplasmic 336–8, 339, 340–1
 - large genomes 311
 - life-long association with host 287
 - linear 287, 295
 - replication 286–8
 - RNA polymerase encoding 200
 - vascular plant infections 307
- DNA–RNA hybrids 192, 194
- domestic animals 7
- double-stranded DNA (dsDNA) **58**
 - baculovirus virion 333
 - genome length measurement 156
 - rate zonal sedimentation 157
- double-stranded RNA (dsRNA) 28, 56, 57, **58**, 233
 - IFN antiviral state trigger 104
 - IFN induction 103
 - renaturation rates 159
- drugs *see* antiviral drugs
- dsRNA-dependent protein kinase 104, 105

- Ebola virus 7, **23**, 259, 266, 386
- echoviruses 241
- eclipse period 182
- EcoRI* restriction enzyme 212, 213
- efavirenz 109
- effective dose, median (ED₅₀) 104
- Egyptian mummies 6
- electron microscopy 119–23
 - DNA genome length measurement 156
- encephalitis 7, 41
 - bunyaviruses 275
 - coxsackievirus 241
 - favorable prognosis 42–3
 - flavivirus 241
 - grave prognosis 41–2
 - herpes 42
 - mosquito-borne 241, 247
 - neonatal herpes simplex virus 89
 - virus replication 24
- encephalopathies
 - prion-induced 40, 283
 - transmissible 283
- endocytosis 64, 65, 66
 - receptor-mediated 83, 238
- endonucleases 195
- endoplasmic reticulum 75
- enteroviruses 41
- Env protein 358, 359, 360, 361, 364
- envelope, lipid 54, 55
 - formation 73, 74, 75
- enzyme-linked immunosorbent assay (ELISA) 91, 92
- enzymes, virus particle counting 125
- epidemiology 4–5
- epidermis 19
- epinephrine 329, 330
- episomes 132
- epitopes 78, 79, 81
 - conformational 79, 85
 - sequential 79
- epizootology 4
- Epstein–Barr-encoded RNAs (EBERs) 331
- Epstein–Barr virus (EBV) 18, **23**, 312, 371
 - immune evasion 303
 - infectious mononucleosis 59
 - latent infection 38–9, 330–1
 - malaria coinfection 332
 - neoplasms 39
- equine encephalitis 7, **22**, 386
- error frequency 232–3
- Escherichia coli*
 - bacteriophage DNA injection 67, 68, 69
 - bacteriophage receptors 67, **68**
 - lac operon 196, 197
 - lytic/lysogenic infection decision 350–1
 - plasmids 210, 211, 212–13, 214–15
- ethics of experiments 26–7
- etiology, viral 19
- eukaryotic cells
 - gene transposition 373
 - splices in transcripts 192, 194–6
 - transcription 188, 190–2, 193, 194–6
 - enhancers 190
 - promoters 188, 190
 - translation 202–4
 - transposable elements 373–4
 - viral replication defenses 102–4, 105
- exocytotic vesicles 75
- exons 191, 192
- exonuclease 188, 195
- Expanded Program on Immunization (WHO) 102
- extremophiles 158

- feline panleukopenia 305, 386
- fibroblasts 129, 130
- filoviruses 258, 259
 - pathogenesis 265–6
- finger nuclease 157
- flavivirus 241, 242
- fusion, viral membrane 65

- G proteins 367, 369
- Gag protein 358, 359, 360
 - variants 366
- Gag–Pol fusion protein 358
- Gag:Prot:Pol proteins 360
- β-galactosidase 212, 220
 - gene 220, 222, Plate 9
- galactosyl ceramide (GalC) 18
- gel electrophoresis 147, 148
 - viral genome size 157, 158
- Geminivirus* 66, 307
- gene therapy, viral vectors 388–90
- genes
 - delivery by viruses 388–90
 - developmental and selective switching 370
 - expression of viral 13, 60
 - transposition 372–4
 - see also* viral genome
 - genetic elements
 - cis*-acting 185
 - trans*-acting 185–6
 - genetic variation 9
 - genetics, virus origins 8–9
 - genital papillomas 6
 - genomic fragments, random reassortment 29
 - genotype 4
 - German measles **23**, 38
 - see also* rubella virus
 - glycoprotein C (gC) 64
 - glycoprotein E (gE) 171, 172
 - glycoproteins 61
 - herpes simplex virus 65
 - membrane-associated 64–5, 66
 - viral envelope formation 73, 75
 - Golgi apparatus 75
 - granulosis viruses (GVs) 333
 - growth factors
 - receptors 367, 369
 - variola virus 37

- growth hormones 367
 growth regulators 367–8, 369
 Guanarito virus 276
 gut-associated lymphatic tissue 17
- habitat disruption 386
 Hantaan virus 275
Hantavirus 7, **22**, 275, 386
see also Sin Nombre virus
 hantavirus adult respiratory distress syndrome (HARDS) 275
 helicases 186, 189
 helper viruses 306
 hemadsorption 134
 hemagglutination 134
 inhibition 92–3, 94
 virus particle counting 124, 125
 hemorrhagic fever 259, 265–6
 bioterrorism use 386
 bunyaviruses 275
 hepadnaviruses 377–81
see also hepatitis B virus; hepatitis C virus
 heparan sulfate 65
 hepatitis 43–4
 chronic 380
 hepatitis A virus 21, **23**, 43, 241
 hepatitis B virus 10, 19, **23**, 43
 cDNA 379
 fulminant 43
 genetic map 378–9
 genome 377–9
 hepatic carcinoma 371
 hepatitis delta virus dependence on 279, 281
 hepatocellular carcinoma 380
 mRNA 379
 neoplasms 39, 43
 oncogenesis 380
 pathogenesis 379–80
 replication cycle 379
 virion 377–9
 hepatitis C virus **23**, 43–4, 385
 hepatic carcinoma 371, 380
 hepatitis delta virus 10, **23**, 44, 279–81
 delta antigen 280
 disease 281
 genome 279–80
 hepatitis B virus dependence 279, 281
 host cell RNA polymerase use 280
 pathology 281
 replication 280
 RNA editing 201
 transcription 280
 hepatitis E virus **23**, 44
- hepatocellular carcinoma 19, 371, 380
 herd immunity 4
 herpes simplex virus (HSV) **23**, Plate 8
 acid blob activator 321
 animal models 33–4
 assembly 323, 325
 capsid 121, 122, 123, 124, Plate 4
 maturation 325, 326–7
 proteins 151
 cell morphology change 134, 135
 DNA
 detection 177, 178
 genome length measurement 156
 PCR techniques 161–2
 replication 189
 encapsidation 323, 324, 325
 encephalitis 42
 gene delivery 388, 389
 gene expression
 early 323
 immediate early 320–1, 322, 323
 late 323
 gene reactivation accommodation 329–30
 genetic map 314, 315, **316–18**
 genome 313–15, 319
 detection by PCR 161
 replication 322, 323
 size measurement 159
 transcription 26
 glycoprotein C 176, 177
 glycoproteins 65
 host defense countering 329, 330
 host entry 319–20
 immune tolerance 89
 immunoaffinity chromatography 176–7
 infection
 latent 13, 32–4, 38–9, 83–4, 88–9, 322, 326, 328–30
 productive 319–21, 322, 323, 324, 325
 IUdR treatment 110
 keratitis 332
 MHCI antigen presentation
 blocking 90, 135–6
 microchip analysis 183
 mRNA characterization 178–9, 181, 182
 nucleocapsid transport 319
 plaque assays 138–9
 pulse labeling of infected cells 166, 167
 quantal assay 140, 141
- reactivation 34, 39, 322, 326, 328–30
 HIV activation 332
 recombinant 220, 222
 recombination 217–18
 release 323, 325
 replication 313–15, 319–21, 322, 323, 324, 325
 replication-deficient 389, Plate 9
 spread 18, 24
 syncytia 63
 tegument proteins 325, 326–7
 thymidine kinase gene 218–19
 transcriptional regulators 321, 322, 323, 326
 virion 313, 314, 325, 326–7
 herpes simplex virus 1 (HSV-1) 32, 41, 312
 capsid Plate 4
 genome 208
 latent infection 326
 herpes simplex virus 2 (HSV-2) 32, 34, 312
 genital 41
 latent infection 326
 herpes zoster virus 19
 herpesvirus
 acyclovir 107
 co-carcinogens 332–3
 envelopment 74, 75
 genetic complexity 312
 latent infection 19, 25, 38–9, 133, 313, 325–33
 neonatal 332
 neurotropic 312, 326
 pathology of infections 331–3
 reactivation 25, 326
 replication 312–33
 transcription changes 199
 alpha-herpesvirus 312
 beta-herpesvirus 312
 gamma-herpesvirus 312
 HflA protease 351
 highly active antiretroviral therapy (HAART) 109
 hit-and-run mechanism of carcinogenesis 371
 HIV 5, 21, **22**
 activation 332
 antiviral drugs 109
 CD4⁺T lymphocytes 61
 chemokines 63
 co-receptors 63, 372, 390
 enabling factors for disease 386
 engineered viral therapy 390
 genetic map 362
 immune system
 destruction 371–2
 target 40

- immunity evasion 358
 immunosuppression 89, 90
 impact 383, 384–5
 incubation period 40
 lymphocyte infection 85
 multiple drug therapy 109–10
 pathogenesis 372, 373
 PCR techniques 161
 protease inhibitors 235
 proteases 73
 receptors 63
 spread 17, 18, 24
 tissue tropism 18
 treatment 385
see also AIDS
 HIV integrase 389
 HIV protease inhibition 109
 holoenzymes 197, 198
 host(s)
 adenovirus interactions 303
 DNA virus life-long association 287
 fate 19
 viral DNA integration 296, 297
 viral spread 15–17
 virus infections 3–5
 virus interactions 5–6
 animal models 26
 evolutionary impact 7–8
 host defense, HSV countering 329, 330
 host factors 17
 host immunity 88
 host range 61
 function in SV40 virus 292
 see also tissue tropism
 human(s)
 experimentation 26
 lymphatic system 77, 78–9
 modes of spread of viruses 21, 22
 virus entry modes 15, 16
 human cell culture 128–31
 human cytomegalovirus (HCMV) 312, Plate 7
 envelopment 74, 75
 immunofluorescence detection methods 171, 172–3
 immunosuppression 90
 infectious mononucleosis 59
 neonatal 89
 uterine infection 89
 human herpesvirus 312
 human herpesvirus 6 (HHV-6) 312
 human herpesvirus 7 (HHV-7) 312
 human herpesvirus 8 (HHV-8) 312, 332
 human immunodeficiency virus *see* HIV
 human papilloma virus (HPV) 299, 300
 carcinogenesis 371
 human papilloma virus 16 (HPV-16) 298, 299, 370
 human T-cell lymphotropic virus (HTLV) 23, 361, 362
 neoplasms 39
 oncogenesis 369–70
 humoral immune system 79
 humoral immunity 77, 78
 hybridoma cells, monoclonal
 antibody generation 169, 170
 hyperimmune responses 86
 hypoxanthine-guanine phosphoribosyltransferase (HGPRT) 170
 immune evasion, virus-mediated 303
 immune memory 82–3, 85, 87
 immune reaction measurement 90–5
 immune reagents, viral protein studies 167–8, 169, 170–7
 immune response 18–19
 assays 26
 B cells 80
 conformational epitopes 85
 cytokines 370
 immune memory effect 85, 87
 initiation by APCs 82–5
 innate 16
 systemic 77
 T cells 80
 viral counter response 88
 virus passage 64
 immune serum 167
 immune system 370
 destruction by HIV 371–2
 development 7
 HIV target 40
 host 135–6
 infected cell interactions 135–6
 see also humoral immune system
 immune tolerance 89
 immunity 4
 active evasion 89–90
 adaptive 15
 cell-mediated 77, 90–1
 control 86–90
 dysfunction 86–90
 evasion 358
 passive 88–9
 host 88
 humoral 77, 78
 lasting 25
 local 80–1, 82
 to reinfection 6
 systemic 81–2, 83
 immunoaffinity chromatography 175–7
 immunofluorescence detection methods 170–1, 172–3, Plate 1
 immunologically naive individuals 4
 immunosuppression 89–90
 drug-induced 90
 HSV infection 331–2
 proto-retrovirus 7
 viral infections 90
in situ hybridization 179–80, 181
 incubation period 15–17
 α -*trans*-inducing factor (α -TIF) 319, 320, 321, 325
 infections
 abortive 131, 132
 accidental target tissue 37–8
 acute 19, 36–7
 asymptomatic 14
 bacterial cells 14
 cell fate 133–6
 cellular specificity 9
 complementing 216, 217
 control by virus titers 137–41
 cytotoxic 61
 cytolytic 61
 dilution endpoint methods 140, 141–2
 eclipse period 182
 focus 136
 host organism effects 3–5
 immunosuppression consequences 90
 inappropriate 64
 initiation 232, 233
 internal sanctuaries 88–9
 late events 69, 71–3, 74, 75
 latent 13, 19
 liver 43–4
 microarray technology 182–3
 mixed 29
 mRNA characterization 178–81, 182
 multiplicity of (MOI) 138, 140–1
 nerve tissue 41
 nonproductive 131–2
 novel 64
 organ system targets 40–4
 outcome in cells 131–6
 pathogenesis 4, 13–19
 persistent 38–9
 population effects 3–5
 poxvirus 340–1
 prevention 96, 97–102
 prodromal period 41–2

- infections (*cont'd*)
 productive 11, 13
 respiratory 37
 semipermissive 132
 sequelae 7
 stages 14–19
 statistical analysis 139–41
 stochastic 14
 suppression 244
 treatment 96
 viral nucleic acid detection/
 characterization 177–83
 viral protein characterization in
 cell 165–8, 169, 170–7
see also reservoir of infection
 infectious dose, median (ID₅₀) 141,
 142
 infectious mononucleosis 59
 influenza
 antigenic drift 88
 epidemics 270–2, 385
 impact 383–4
 pandemic of 1918–1920 7, 37,
 163, 383–4
see also avian influenza
 influenza A 267
 antigenic drift 270
 antigenic shift 271
 epidemics 270–2
 influenza A virus
 amantadine 108–9
 maturation 268, 269, 270
 nucleocapsid generation 268,
 269, 270
 replication 268
 ribonucleoproteins 270
 influenza B 267
 influenza C 267
 influenza virus 19, 23, 37, 267–8,
 269, 270–2
 avian 7, 272
 budding 75
 cap snatching/stealing 268,
 269
 hemagglutination 124, 125
 maturation 268, 269, 270
 mRNA synthesis 268, 269, 270
 Mx protein 104
 novel chicken 64
 nucleocapsid generation 268,
 269, 270
 replication 267–8, 269, 270
 ribonucleoproteins 268, 269,
 270, 271–2
 sialic acid residues 61
 variants 25
 informed consent 26
 initiation factors (IFs) 202, 203,
 204–5
 insect viruses 333–4
 integrase 358, 359
 interferon (IFN) 14
 activity measurement 104
 antitumor activity 103, 104
 antiviral proteins 104, 106
 antiviral response 7, 16, 102–4,
 105
 antiviral state 104
 expression 104, 105
 induction 103, 233
 toxic effects 104
 types I and II 103
 α -interferon (IFN- α) 103
 β -interferon (IFN- β) 103
 γ -interferon (IFN- γ) 341, 370
 internal ribosome entry site (IRES)
 235, 239
 intracellular adhesion molecules
 (ICAMs) 61
 intracellular trafficking proteins 64
 introns 191, 192
 iodouridinedeoxyriboside (IUDR)
 110
 iontophoresis 34
 JC virus 38, 288–9, 291
 Jenner, Edward 97–8, 341
 Junin virus 276
 Kaposi's sarcoma 332
 Kaposi's sarcoma herpesvirus 312
 Koch's rules 25–6
 Korean hemorrhagic fever 275
 Kozak sequence 202, 203
 kuru 10, 282
 La Crosse encephalitis virus 22, 272,
 273, 275, 333
 lac operon 196, 197, 198
 large T antigen 292, 294, 296, 297
 Lassa fever virus 276, 386
 Last Universal Common Ancestor
 (LUCA) 9
 latency 13, 19
 adeno-associated virus 306, 389
 bacteriophage λ 346, 348–50
 Epstein-Barr virus 38–9, 330–1
 herpes simplex virus 13, 32–4,
 38–9, 83–4, 88–9, 326,
 328–30
 cycle 322
 herpesvirus 19, 25, 38–9, 133,
 313, 325–33
 latency-associated transcripts (LATs)
 180, 322, 329, 330
 lentiviruses 358, 359
 cDNA migration 362, 363, 364
 genetic map 362
 transcription changes 199
see also HIV
 lethal dose, median (LD₅₀) 141
 Leviviridae 253
 liver
 cirrhosis 44, 385
see also hepatitis
 lopinavir 109
 lymph nodes 77, 78
 lymphatic system 16–17
 human 77, 78–9
 lymphocytes
 clonal selection of immune
 reactive 85, 86
 HIV infection 85
see also B cells; T cells
 lymphocytic choriomeningitis virus
 (LCMV) 89, 275–6
 lymphotropic viruses 89
 lyophilization 100
 lysogeny 11, 346, 348, 349, 350
 Machupo virus 276, 386
 macromolecule migration rate 147
 macrophages, HIV internalization
 85, 372
 “mad cow” disease *see* bovine
 spongiform encephalopathy
 (BSE)
 maize streak virus 307
 major histocompatibility complex
 (MHC) 82
 antigen presentation blocking 90
 type I 82, 83
 inhibition 135–6
 type II 83
 malaria, EBV coinfection 332
 Marburg virus 259, 265–6, 386
 measles 19, 22, 97, 259, 264
 antigens 39
 persistence 87–8
 eradication 387
 virgin populations 39
 membrane envelope, viral 54, 55
 meningitis 41
 echovirus in infants 241
 mental illness 267
 messenger RNA (mRNA) 57
 abundance estimation 159–60
 characterization during infection
 178–81, 182
 coronavirus 248–50
 eukaryote 191, 192, 193
 exons 191, 192
 herpes simplex virus 178–9, 181,
 182
 introns 191, 192
 maturation 191, 193
 polyadenylation signals 191, 192

- polycistronic 204
 posttranscriptional modification
 of precursor 191, 192
 processing 191, 193
 RNA virus
 genome expression 232
 production 242–4
 sense strand 191
 splicing 191, 192, 193
 subgenomic 244, 246
 transcription 185
 translation termination
 suppression 205
 truncated 244
 viral genome type 207
 metastasis 299
 microarray technology, infected cell
 182–3
 microarrays 136
 microchip analysis 136, 182–3
 microglial cells 18
 microscopy
 atomic force 123–4
 confocal 170–1, 172, Plates 7 and
 8
 cryo-electron 121, 122
 electron 119–23, 156
 mitochondrion 8
 molecular mimicry 88
 monoclonal antibodies 168, 169,
 170
 monocytes 17
 Montague, Lady Mary Wortley 97
Morbillivirus 264
 mosaicism 13
 mouse mammary tumor virus 361,
 362
 multiple cloning sites (MCSs) 212
 multiple sclerosis 19
 persistent infections 39
 viral infection 87–8
 multiplicity of infection (MOI)
 138, 140–1
 mumps 259, 264
 murine leukemia virus 361, 368
 mutations 4
 analysis 216–18
 back 99
 complementation 216, 217
 frame shift 216
 isolation 218
 protein changes 214–18
 recombination 216–18
 replication prevention 132
 screening 219
 selection 218
 SV40 capsid protein 64
 virulence alteration 219
 Mx protein 104
c-myc gene 371
 myelitis 41
 myeloma cells 170
 myxoma virus 9, 23
 biological control 27
 natural killer (NK) cells 370
 Nazi Germany 26
 neoplasms 39
 neural tissues
 herpesvirus infection 312, 326
 picornaviruses 240, 241
 neurotropic viruses 17, 89
 neutralization tests 91–2, 93
 Northern blot 174
 nuclear polyhedrosis viruses (NPVs)
 333
 nucleic acids
 annealing 158–9, 160
 characterization in infected cells
 178–83
 complementary strands 158
 complexity measurement 158–60
 detection in infected cells 177,
 178
 hybrid generation 158, 160
 hybridization 178
 reannealing 158–9, 160
 renaturation rates 158–60
 size measurement 158–60
 see also DNA; RNA
 nucleoproteins
 helix 52, 54
 icosahedral 52, 53–4
 nucleotides, palindromic sequences
 110
 octamer-binding protein 1 (oct1)
 320
 2',5'-oligoA synthetase 104, 105
 oligonucleotide polymers, short 110
v-onc 361, 362, 367, 371
 oncogenes 39, 296, 367, 368, 370,
 371
 oncogenesis 370–1, 380
 oncogenic transformation 299
 oncornaviruses 358, 359
 cDNA migration 362, 363, 364
 genetic map 361–2
 growth regulation transcriptional
 control alteration 368
 oncogenes 371
 transformation
 growth stimulation of
 neighboring cells 369–70
 through viral oncogene actions
 367–8
 open reading frame (ORF) 234
 translational 202–3
 operators 196, 197
 operons 196–7, 198
 organelles, eukaryotic 8
 origin binding protein 186
 origin of replication (ori) site 186,
 189
Orthopoxvirus 97, 337
Orthoreovirus 276, 279
 p53 tumor suppressor gene 296,
 299, 370
 packaging signal (*pac*) 71
 palindromic sequences of nucleotides
 110
 palliative treatment 6
 papillomavirus 21, 23
 neoplasms 39
 replication 296, 298–9, 300
 serotypes 88
 warts 21, 38, 299, 300
 papovaviruses 371
 replication 135, 288–99
 parainfluenza 259
Paramecium bursaria Chlorella-1
 virus (PBCV-1) 351–2
 paramyxovirus 258, 259
 pathogenesis 264–5
 parvovirus
 canine 21, 386
 genome 287
 potential therapeutic applications
 306
 replication 305–6
 passages, multiple 31
 Pasteur, Louis 98
 pathogenesis 4, 13–19
 animal models 25–34
 pathogens 7, 9
 drug-resistant 90
 pBR322 genetic map 210, 211,
 212–13, 214–15
 peripheral nervous system, viral
 spread 17
 peroxidase tags 172–3
 Peyer's patches 17
 pGEM genetic map 210, 211,
 212
 phenotype 29
 phleboviruses 274–5
 picornaviruses 38
 cytopathology 239–41
 neural tissues 240, 241
 replication 234–5, 236, 237, 238,
 239–41
 pilot protein 69, 73
 placebo 26
 plant cells 11, 12, 13
 cultures 128
 plant pathogens 7

- plant viruses
- cauliflower mosaic virus 380–1
 - cell entry 65–7
 - DNA viruses 307
 - plaque formation 136, 137
 - replicase 252
 - RNA genome replication 251–3
 - vectors 66, 307
- plaque assays 128, 136, 137, 138–9
- replica plating 217–18
- plaque-forming units (PFUs) 136, 137
- particle ratio 137–8
 - statistical analysis 139, 140
- plasmids, viral genome fragment
- cloning 210, 211, 212–13, 214–15
- plasmodesmata 67
- pneumoviruses 264
- Poisson analysis 139–40
- polarity, opposite 232
- poliomyelitis 239–41
- Egyptian mummies 6
 - eradication 102, 241, 387
 - paralytic 18, 38, 240
- poliovirus 22, 38, 239
- amino acid analogues 237
 - assembly 239, 240
 - capsid proteins 148–9, 150, 235, 236, 237, 238, 239
 - clearance 19
 - cytopathology 239–41
 - disease 239–41
 - empty capsid formation 72
 - genetic map 235, 236, 237
 - internal ribosome entry site (IRES) 235, 239
 - intracellular adhesion molecules 61
 - mode of spread 16–17
 - nucleus removal 234
 - ORF 236, 237
 - polyA tail 235
 - procapsid 239, 240
 - proteases 235, 236
 - proteins 235, 236, 237
 - precursor 235, 236, 237, 238, 239, 240
 - pulse-chase experiment 237
 - pulse labeling of infected cells 166–7
 - receptor 18, 38, 61, 63, 239–40
 - receptor-mediated endocytosis 238
 - replicase 236, 237, 238, 239
 - replication 234–5, 236, 237, 238, 239, 240
 - RNA 235, 236, 238, 239
 - serotypes 88
 - termination 199, 200, 201
 - translation 204–5
- propagation of viruses 4
- prophage 346, 350
- protease 358, 359
- maturation 71
- protease inhibitor drugs 109, 235
- protein kinases 368, 369
- proteins, viral 13, 17
- antigenic 101
 - antigenic determinants 78, 81
 - antigenic responses 85
 - buoyant density differences 145–6
- capsid 147–8
- differing molar amounts 149, 150, 151
 - poliovirus 148–9, 150
- cell surface changes 134
- characterization in infected cell 165–8, 169, 170–7
- immune reagents 167–8, 169, 170–7
- immunoaffinity chromatography 175–7
- immunofluorescence detection methods 170–1, 172–3
- immunological structure 78–9, 81
- mutation effects 214–18
 - non-structural 144
- poliovirus 235, 236, 237
- pulse labeling 165–7
- structural 51, 144–9, 150, 151
- isolation 145–6
 - size fractionation 147–9, 150, 151
- synthesis mechanisms 201–5
- tegument 75
- transfection 69, 70
- viral-encoded 9, 71
- proteosomes 82
- proto-oncogenes 367, 368
- proto-retrovirus 7
- prototropy 127
- provirus 357–8
- pseudorabies virus 65
- exocytosis 74, 75
- public health measures, breakdown 386
- pUC19 genetic map 210, 211, 212
- pulse-chase experiment, poliovirus 237
- pulse labeling of viral proteins 165–7
- quantal assay 140, 141
- quasi-species swarm 234
- vaccine 234, 240–1
- Sabin strains 99, 100
 - Salk 100
 - VPg protein 236, 237, 238, 239
- polyadenylation signals 191, 192
- polydnavirus 8
- immunosuppression 89–90
- polyhedrin protein 334
- polymerase chain reaction (PCR) 136
- viral genome detection/characterization 160–3
- polyomavirus
- genetic map 289–90
 - replication 288–9, 290, 291–3, 294, 295–6, 297
 - in situ* hybridization 180, 181
 - transcription 289–90
- populations, virus infections 3–5, 24–5
- posttranscriptional processing 199–201
- potato spindle tuber viroid 281
- poxvirus 19
- cellular proliferation induction 338
 - core particles 338, 339
 - DNA replication 340
 - growth factor 340–1
 - infections 340–1
 - mode of spread 340
 - mortality 340
 - mouse model 27–8
 - mRNA transcription 340
 - partial uncoating 338, 339
 - pathogenesis 340–1
 - replication 337–8, 339, 340–1
 - transcription enzymes 337–8
 - virion 337–8, 340
- pregnancy
- hepatitis E virus 44
 - rubella 38, 248
- Pribnow box 197
- primary cells 129–30, 131
- primase 186, 189
- prion diseases 282–3
- incubation period 40
- prion proteins (PrPs) 282, 283
- prions 10, 23, 282–3
- procapsid 71
- progressive multifocal leukoencephalopathy (PML) 291
- prokaryotic cells
- inducible genes 198
 - promoter 197–8
 - RNA polymerase 197, 198, 199
 - transcription 196–9, 200, 201
 - initiation 197–9, 200, 201

- R-loop mapping 192
- rabbits, myxoma virus 9
- rabies
- dumb form 42
 - furious form 41–2
 - grave prognosis 41–2
 - incubation period 40
 - pathogenesis 264
 - spread 264
 - vaccine 98
- rabies virus 7, 18, **23**, 24, 259
- acetylcholine receptors 61
 - animal models 30–1, 31–2
 - immunofluorescent detection
 - Plate 1
 - replication 264
 - virulence 31
- rate zonal sedimentation 156–7
- Rb tumor suppressor gene 296, 299, 370
- reactivation (recrudescence) 13
- bacteriophage λ 346, 348–50
 - herpes simplex virus 34, 39, 322, 326, 328–30
 - herpesvirus 25, 326
- reannealing 158–9
- recA protease 351
- receptor-mediated endocytosis 83, 238
- receptors 18
- cellular 61, 62, 63–4
- recognition, virus 60
- recombinant DNA technology 343
- recombinant virus 98, 100
- generation 219–22
- recombination
- herpes simplex virus 217–18
 - homologous DNA 220, 221–2
 - live vaccine with viral genome 99
 - mutations 216–18
 - vaccines 100
- refrigeration of vaccines 99–100, 102
- reovirus 276, 277, 278–9
- genotypes 30
 - mouse infections 28–30
 - pathogenesis 279
 - replication cycle 276, 278–9
 - structure 276, 277
- replicase
- bacteriophage Q β 254, 255
 - coronavirus 250
 - plant viruses 252
 - poliovirus 236, 237, 238, 239
- replication 11, 13, 17
- adenovirus 299, 301–3, 304
 - bacteriophage T4 345–6, 347
 - bacteriophage T7 342–3
- bacteriophages with RNA genome 253–5
- baculovirus 333–4
- brome mosaic virus 252–3
- continual 15
- coronavirus 248–50
- cowpea mosaic virus 252
- cycle 60–75
- DNA viruses 286–8
- drug targeting 106–10
- eukaryotic cell-based defenses 102–4, 105
- flavivirus 241, 242
- hepatitis B virus 379
- hepatitis delta virus 280
- herpes simplex virus 313–15, 319–21, 322, 323, 324, 325
- herpesvirus 312–33
- impediments 132
- papillomavirus 296, 298–9, 300
- papovaviruses 288–9, 290, 291–3, 294, 295–6, 297, 298–9
- parvovirus 305–6
- picornavirus 234–5, 236, 237, 238, 239, 240
- plant viruses with RNA genome 251–3
- plasmid-like 299
- poliovirus 234–5, 236, 237, 238, 239, 240
- polyomavirus 288–9, 290, 291–3, 294, 295–6, 297
- rabies virus 264
- reovirus 276, 278–9
- retroviruses 357–8, 362, 363, 364–6
- RNA viruses 232–4
- positive sense 234–55
- Sindbis virus 243–4, 245, 246, 246–7
- SV40 virus 288–9, 290, 291–3, 294, 295–6, 297
- tobacco mosaic virus 252
- togavirus 243–4, 245, 246–8
- vesicular stomatitis virus 259–60, 261, 262–4
- yellow fever virus 24, 241, 242
- see also* RNA viruses, negative (–)-sense; RNA viruses, positive (+)-sense
- replication fork 186, 187
- replicative intermediates (RIs) 232, 233
- repressors 196, 197
- reservoir of infection 15, 19, 21
- human 21, 24
 - vertebrate animal 24
- resolvase gene 373
- respiratory syncytial virus 264–5
- Reston virus 266
- restriction endonucleases 110–11, 157, 158
- cleavage sites 208–10
- restriction mapping 208–10
- reticulocytes, rabbit 181
- retroelements 374
- retrointrons 374
- retroposons 374
- retrotransposons 374–5
- retroviruses 8, 356–7
- antiviral drugs 109
 - cancer induction 371
 - capsid assembly/maturation 363, 364, 366
- cDNA
- generation 362, 363
 - migration 362, 363, 364
 - synthesis 364–6
- cellular genetic elements 372–5
- classification 357
- Env protein 358, 359, 360, 361, 364
- Gag protein 358, 359, 360
- variants 366
- gene delivery 388, 389
- genetic map 360–2
- genome 359–60
- genomic RNA conversion to cellular DNA 357
- immunosuppression 89
- infection initiation 362, 363, 364
- long terminal repeats 362, 363, 366, 368
- generation 364–6
- matrix protein 366
- molecular biology 358–62
- mRNA transcription/translation 366
- oncogene activation 367, 368
- proteases 73
- proto-oncogenes 367, **368**
- replication 362, 363, 364–6
- strategies 357–8
- reverse transcriptase assays 125
- structural proteins 358, 359
- transcription 366
- transformation 366–71
- viral oncogene actions 367–8
- translation 366
- termination suppression 205
- reverse transcriptase 125
- mRNA conversion to cDNA 159–60
- reverse transcriptase Pol 357, 358, 359
- cDNA synthesis 364–6

- rhabdoviruses 258–9
 cytopathology 264
 disease 264
 plant **23**, 251, 259
see also rabies virus
- rheumatic fever, group A
 streptococcus 88
- rheumatoid arthritis 19
- rhinovirus 21, **23**, 37, 241
- ribonuclease 156–7
- ribonucleoprotein(s) 262
 bunyavirus 273, 274
 influenza virus 268, 269, 270, 271–2
- ribonucleoprotein (RNP) complex 232, 259, 261
- ribosomal RNA (rRNA) 186
- ribosomes 254
- ribozymes 280
- Rift Valley Fever 7, 275
- rimantadine 108, 109
- rinderpest 264, 265
- ritonavir 109
- RNA 51
 complementary strand 232
 complexity measurement 158–60
 editing 201
 hybridization from DNA 179–81
 PCR techniques 162–3
 renaturation rates 158–60
 size measurement 158–60
 splicing patterns 163
 synthesis detection 177
 tobacco mosaic virus 71
 VA 301, 303
 virion 234
 Watson–Crick base-pairing rules 232, 233
see also double-stranded RNA (dsRNA); messenger RNA (mRNA); ribosomal RNA (rRNA); single-stranded RNA (ssRNA); small nuclear RNA (snRNA)
- RNA polymerase
 encoding by DNA viruses 200
 host cell use by hepatitis delta virus 280
 prokaryotic 197, 198, 199
- RNA polymerase II (pol II) 188, 190
- RNA polymerase III (pol III) 301
- RNA viruses 51, 54, 56, 231–2
 antigenic drift 88
 genome
 detection 177
 expression 232
 multipartite 258–60, 261, 262–7
 multipartite 258, 267–8, 269, 270–2, 273, 274–6
 open reading frame 234
 quasi-species swarm 234
 replication
 DNA as intermediate 232
 error rate in genome 233
 RNA-directed 232–4
 ribonucleoprotein complex 232
 translation termination suppression 205
- RNA viruses, negative (–)-sense 57, **58**, 258
 replication
 arenaviruses 275–6
 bunyaviruses 272, 273, 274–5
 double-stranded RNA genomes 276, 277, 278–9
 influenza virus 267–8, 269, 270–2
 multipartite genome 258–60, 261, 262–7
 multipartite genome 258, 267–8, 269, 270–2, 273, 274–6
- RNA-dependent transcriptase 258
- RNA viruses, positive (+)-sense 57, **58**
 encapsidation 239, 240, 241, 242
 genomic structure **251**
 mRNA production 242–4
 replication 234–55
 encoding more than one ORF 242–4, 245, 246–51
 encoding single large ORF 234–5, 236, 237, 238, 239–41, 242
 multiple translational reading frames 248–51
 viral protein translation 234
- RNase H 364, 365, 379
- rodents
 arenavirus carriers 276
 hantavirus spread 386
- Rotavirus* 279
- Rous sarcoma virus 361, 362
- rubella vaccination 248
- rubella virus **23**, 38, 247–8
 immune tolerance 89
- Rubulavirus* 264
- Sabin polio vaccine 99, 100
- SalI* restriction enzyme 213, 214–15
- Salk polio vaccine 99
- Saquinovir 109
- SARS (severe acute respiratory syndrome) 7, 251, 424
- schizophrenia 19
- scrapie 10, 282, 283
- Sendai virus 264, 265
- senescence 129
- Serratia marcescens* biological weapon 387
- severe acute respiratory syndrome *see* SARS
- severe combined immunodeficiency (SCID), mouse 30
- sex pilus 67
- sexually transmitted disease 5–6, 371, 386
- Shine–Dalgarno sequence 205
- shingles 312
- sialic acid residues, influenza virus 61
- Sin Nombre virus 275, 386
- Sindbis virus
 gene expression 244
 replication 244, 245, 246, 246–7
 viral genome 243
- single-stranded DNA (ssDNA) **58**
 gene compression 307, 308
 rate zonal sedimentation 157
 restriction mapping 210
 unhybridized loop 192
- single-stranded DNA bacteriophage 307–9
- single-stranded DNA viruses 287
 plant infections 307
 replication 305–9
- single-stranded RNA (ssRNA) 56, **58**
 rate zonal sedimentation 156–7
 replication 232–4
 restriction mapping 210
- small nuclear RNA (snRNA) 191, 192
- small t antigen 292, 294
- smallpox 6–7, **23**, 37
 animal models 27
 biological terrorism potential 341, 387
 replication genes 337
 terrorism threats 98
 vaccination 97–8
 vaccines 338, 341, 387
 variola 97, 340
 virgin populations 39
- SOS repair system 351
- Southern blot 174, 177
- Spanish influenza pandemic 7, 37, 163, 383–4
- ssDNA-binding proteins 186, 189
- St Louis encephalitis 241
- staphylococcus A proteins 173–4, 174–5
- stem cells 370

- stimulation index 90
- streptococcus G proteins 173–4
- streptococcus group A, rheumatic fever 88
- structure of viruses 51–2, 53–4, 55
- subacute sclerosing panencephalitis (SSPE) 39, 87
- subviral pathogens 279–83
- suppression, genetic 244
- SV40 virus 64
- agnoprotein 294, 295
 - attachment 293, 294
 - early gene expression 290, 293
 - early transcription unit 290, 291–2
 - entry 293, 294
 - genetic map 289–90, 291–2
 - genome 208, 289, 291–2
 - host–range function 292
 - infection
 - abortive 295–6, 297
 - pattern 291
 - productive 292–3, 294, 295
 - late transcription unit 290, 292
 - mRNA 292–3
 - nonpermissive cell transformation 296, 297
 - polio vaccine contamination 100
 - polyadenylation region 292
 - replication 288–9, 290, 291–3, 294, 295–6, 297
 - T antigen 292, 293, 294, 295, 296, 297
 - TATA box 291
 - transcription 289–90
 - viral DNA integration in host cell 296, 297
- swine influenza 384
- symbiosis, host–virus relationship 8, 352
- syncytia, herpes simplex virus 63
- syndromes 19
- syphilis, Tuskegee study (USA) 26
- T-cell immunity *see* cell-mediated immunity
- T cells 17, 18
- antigen-binding sites 77–8
 - clonal selection 85
 - effector 18–19
 - immune response 80
 - proliferation 370
 - see also* CD4⁺T cells; CD8⁺T cells
- T_C cells 85
- T_H cells 85
- T_S cells 85, 86
- target tissue/organ 16, 17
- accidental 37–8
 - receptors 18
- TATA box 188, 190, 191
- SV40 virus 291
- 3TC 109
- tegument proteins 75
- telomers 130
- tenofovir 109
- termination factor 199, 201
- terrorism *see* bioterrorism
- therapeutic agents 9, 388–90
- therapeutic index 106
- thymidine kinase 107, 218–19
- tissue culture infectious dose, median (TCID₅₀) 141, 142
- tissue tropism 18, 40, 61
- entry-mediated 63
 - neural 89
 - see also* host range
- tobacco mosaic virus (TMV) 69, 71, 251
- plaque formation 137
 - replication 252
 - RNA 71
- togaviruses
- cytopathology 246–8
 - disease 246–8
 - replication 243–4, 245, 246–8
 - transmission 247
- tomato golden mosaic virus 307
- tomato spotted wilt 23
- topoisomerases 186
- tospoviruses 251, 274–5
- α -*trans*-inducing factor (α -TIF) 319, 320, 321, 325
- transcriptase, viral 232
- coronavirus 250
 - RNA-dependent 258
- transcription 185
- bacteriophage T7 342–3
 - coronavirus 248–50
 - discontinuous 248–9, 250
 - eukaryotic 188, 190–2, 193, 194–6
 - hepatitis delta virus 280
 - leader-primed 248–9, 250
 - polyomavirus 289–90
 - prokaryotic 196–9, 200, 201
 - retroviruses 366
 - SV40 virus 289–90
 - termination factor 199, 201
 - virus-induced changes 199–201
- transcription factors 188, 190, 368, 369
- transcription/translation, coupled 204
- transcriptional regulators for HSV 321, 322, 323
- transfection 69, 70, 101
- DNA 220, 221–2
- transfer blots 174
- transfer RNA (tRNA) 186
- initiator 204–5
- transformation 11
- animal cells 11, 13
 - focus 137, 138
 - nonpermissive cells 296, 297, 303
 - oncornaviruses 367–70
 - retroviruses 366–71
 - transitory 296, 297
- translation
- bacteriophage mRNA 253–5
 - eukaryotic 202–4
 - initiation factors 202
 - open reading frame 202–3
 - prokaryotic 204–5
 - retroviruses 366
 - virus-induced changes 205
- translocation 64
- transmissible encephalopathy 283
- transmission of viruses 22
- transporter proteins (TAPs) 82, 83
- transposable elements 373–5
- transposase gene 373
- transposons 373
- tropism 17
- tuberculosis, antibiotic-resistance 90
- tulip color variation 13
- tumor antigens 77
- tumor cells, primary cell
- transformation 131
- tumor suppressor genes 39, 135, 296
- function blocking 371
- tumour necrosis factor (TNF) 341
- Tuskegee syphilis study (USA) 26
- ubiquitins 82
- United Kingdom, BSE and beef industry 10, 283
- United States
- biological weapons testing 387
 - Tuskegee syphilis study 26
- vaccination/vaccines 4, 97–102
- adjuvants 101
 - antigenic proteins 101
 - antiviral 97
 - design 101
 - developing world 100
 - development 101
 - DNA 101
 - freeze drying 100
 - hepatitis C virus 385
 - influenza virus 25
 - Jennerian 98
 - killed-virus 98, 100
 - live-virus 98, 99–101

- vaccination/vaccines (*cont'd*)
 poliovirus 234, 240–1
 production 98–101, 102
 prophylactic 9, 98
 recombinant virus 98, 100
 refrigeration 99–100, 102
 rubella 38, 248
 smallpox 97–8, 338, 341, 387
 socioeconomic problems 102
 subunit 99, 101
 use 102
- vaccinia virus 18, 98
 replication 338, 339, 340
 replication genes 337
- varicella zoster virus **23**, 312
 glycoprotein E 171, 172
 immunofluorescence detection
 methods 171, 172–3
 immunosuppression 90
 latent infection 38
 spread 24
 transfection 70, Plate 3
see also chicken pox; herpes zoster virus
- variola major 97, 340
 variola minor 97, 340
 variola virus *see* smallpox
- variolation 97
- vectors 15
 gene therapy 388–90
 human infections 21, 22
 pathogenic viruses **22–3**
 plant viruses 66, 307
see also arthropod vectors
- vesicles 19
- vesicular stomatitis virus
 budding 75
 capping 259–60, 261
 in cattle 7, 264
 defective genome 223
 generation 259–60, 261
 genome 259, 260
 host shut-off mechanism 263
 lesions 264
 Mx protein 104
- negative-sense virion RNA
 260–2, 263
- polyA tails 260
- polyadenylation 259–60, 261
- recombinant 390
- replication 259–60, 261, 262–4
- ribonucleoproteins 259, 261, 262
- virion 259, 260
- viral coat proteins 13
- viral genome 3, 51, 208
 alterations in laboratory
 replication 219–23
 ambisense 274
 attenuation 219
 characterization techniques 26,
 151–4, 155, 156–63
 fragment cloning with bacterial
 plasmids 210, 211, 212–13,
 214–15
 gel electrophoresis 157, 158
 genetic manipulation 9, 214–19
 infections 11
 introduction into cells 69, 70
 latency-associated transcripts 180
 map units 208
 mRNA generation 207
 mutations 214–18
 PCR techniques 160–3
 rate zonal sedimentation
 156–7
 replication 13, 60
 restriction endonuclease cleavage
 sites 208–10
 sequence analysis 151–4
 Sindbis virus 243
 size measurement 155, 155
 synthesis detection 177, 178
 vesicular stomatitis virus 259,
 260
 virulence 219
see also genes
- viremia 16
- virion 51
 assembly 60
 envelope generation 75
- molecular ratio of structural
 proteins 147–8
 release 69, 71–3, 74, 75
- viroids 10
 plant 281–2
- virology 6
- virulence 4
 mutation alterations 219
- rabies virus 31
- Spanish influenza pandemic 7
- viral genome 219
- virus origins 8–9
- virus particles
 coating 119–20, 121
 defective 10, 75, 132–3, 222–3
 disruption 147
 enumeration 122–3, 125
 enzyme techniques 125
 hemagglutination titration 124,
 125
 PFU ratio 137–8
 shadowing 120, 121
 staining 119–20
 visualization 119–24
- VPg protein 236, 237
- warts 21
 formation 299, 300
 keratinized tissue 38
- wasps, parasitic 7–8, 89–90
- Watson–Crick base-pairing rules
 158, 186, 232, 233
- weather patterns 386
- West Nile virus 241, 386
- Western blot 174
- World Health Organization (WHO)
 102
- x-ray crystallography 55, 56, 123–4,
 Plate 2
- yellow fever 7, **22**, 333
 replication 24, 241, 242
- zoonosis 22, 24